Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Global Tech ETF (IXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Global Tech ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.25 (market cap $4.04B), while iShares Global Tech ETF trades at $142.15. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Global Tech ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | IXN | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $149.74 |
52-Week Low | $12.30 | $94.42 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
IXN trades at $142.26, up 2.04% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong momentum near resistance at $142. Recent news highlights its global tech exposure, though some analysts express caution on valuations.
The outlook is mixed; technical strength supports near-term upside, but high expectations and concentration risk warrant caution. Investors should weigh growth potential against valuation concerns in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →
